SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Active Psoriatic Arthritis
Conditions
Active Psoriatic Arthritis
Trial Timeline
Apr 19, 2017 → Sep 24, 2019
NCT ID
NCT02980692About SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBO is a phase 2 stage product being developed by Sun Pharmaceutical for Active Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02980692. Target conditions include Active Psoriatic Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Active Psoriatic Arthritis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02980692 | Phase 2 | Completed |
Competing Products
20 competing products in Active Psoriatic Arthritis